Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
1. A method of treating, or reducing the incidence of, a symptom of atopic dermatitis in a human patient,
the method comprising subcutaneously administering to the patient a series of doses of an anti-human IL-31RA antibody that comprises an H chain variable region as set forth in SEQ ID NO: 7 and an L chain variable region as set forth in SEQ ID NO: 8,
wherein the amount of the anti-human IL-31RA antibody in each dose is 30 mg/body, and
wherein the interval between each dose and the next is 4 weeks.
2. The method of claim 1 , wherein the symptom is pruritus.
3. The method of claim 1 , wherein the anti-human IL-31 RA antibody comprises a human IgG2 Fc region comprising an amino acid sequence with glutamic acid at EU numbering position 419.
4. The method of claim 1 , further comprising administering a topical composition to the patient, wherein the topical composition comprises a topical steroid or a topical calcineurin inhibitor and is administered before, simultaneously with, or after at least one administration of the anti-human IL-31RA antibody.
5. A method of treating, or reducing the incidence of, a symptom of atopic dermatitis in a human patient,
the method comprising administering to the patient an initial dose of an anti-human IL-31RA antibody, followed by subcutaneously administering two or more continuous doses of the anti-human IL-31RA antibody,
wherein the amount of the anti-human IL-31RA antibody in each of the continuous doses is 30 mg/body,
wherein the interval between each two sequential administrations of the continuous doses is 4 weeks, and
wherein the anti-human IL-31 RA antibody comprises an H chain variable region as set forth in SEQ ID NO: 7 and an L chain variable region as set forth in SEQ ID NO: 8.
6. The method of claim 5 , wherein the symptom is pruritus.
7. The method of claim 5 , wherein the anti-human IL-31 RA antibody comprises a human IgG2 Fc region comprising an amino acid sequence with glutamic acid at position 419 (EU numbering).
8. The method of claim 5 , further comprising administering a topical composition to the patient, wherein the topical composition comprises a topical steroid or a topical calcineurin inhibitor and is administered before, simultaneously with, or after at least one administration of the anti-human IL-31RA antibody.
9. The method of claim 8 , wherein the method produces a reduction in symptoms of atopic dermatitis in the patient that is greater than the reduction in symptoms induced by treatment with the anti-human IL-31RA antibody alone.
10. The method of claim 8 , wherein the method permits a lower dosage of the topical composition to be administered than would be needed when the topical composition is administered as a single agent to the patient in the absence of treatment with the anti-human IL-31RA antibody, in order to produce a comparable decrease in symptoms of atopic dermatitis.
11. A method of treating, or reducing the incidence of, a symptom of atopic dermatitis in a human patient,
the method comprising subcutaneously administering to the patient a series of doses of an anti-human IL-31RA antibody that comprises an H chain as set forth in SEQ ID NO: 9 and an L chain as set forth in SEQ ID NO: 10,
wherein the amount of the anti-human IL-31RA antibody in each dose is 30 mg/body, and
wherein the interval between each dose and the next is 4 weeks.
12. The method of claim 11 , wherein the symptom is pruritus.
13. The method of claim 11 , further comprising administering a topical composition to the patient, wherein the topical composition comprises a topical steroid or a topical calcineurin inhibitor and is administered before, simultaneously with, or after at least one administration of the anti-human IL-31RA antibody.
14. A method of treating, or reducing the incidence of, a symptom of atopic dermatitis in a human patient,
the method comprising administering to the patient an initial dose of an anti-human IL-31RA antibody, followed by subcutaneously administering two or more continuous doses of the anti-human IL-31RA antibody,
wherein the amount of the anti-human IL-31RA antibody in each of the continuous doses is 30 mg/body,
wherein the interval between each two sequential administrations of the continuous doses is 4 weeks, and
wherein the anti-human IL-31 RA antibody comprises an H chain as set forth in SEQ ID NO: 9 and an L chain as set forth in SEQ ID NO: 10.
15. The method of claim 14 , wherein the symptom is pruritus.
16. The method of claim 14 , further comprising administering a topical composition to the patient, wherein the topical composition comprises a topical steroid or a topical calcineurin inhibitor and is administered before, simultaneously with, or after at least one administration of the anti-human IL-31RA antibody.
17. The method of claim 16 , wherein the method produces a reduction in symptoms of atopic dermatitis in the patient that is greater than the reduction in symptoms induced by treatment with the anti-human IL-31RA antibody alone.
18. The method of claim 16 , wherein the method permits a lower dosage of the topical composition to be administered than would be needed when the topical composition is administered as a single agent to the patient in the absence of treatment with the anti-human IL-31RA antibody, in order to produce a comparable decrease in symptoms of atopic dermatitis.